Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice

Earnings Outlook Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. These revisions helped boost PSTX's consensus estimate, increasing from -$1.67 to -$1.61 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period. Given these factors, it shouldn't be surprising that PSTX is a #2 (Buy) stock and boasts a Momentum Score of B. If you're looking for a fresh pick that's ...